You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A High-Speed, User-Friendly, Handheld OCT System for Patients who are Unable to Cooperate

    SBC: Theia Imaging LLC            Topic: 100

    ABSTRACTOptical coherence tomography (OCT) is the gold standard for the diagnosis and monitoring of retinal and optic nerve diseases. Clinical OCT systems (large tabletop devices with chinrest) require a compliant subject, and thus are not suitable for use with infants, young children, and patients who are unable to cooperate for eye imaging (such as from physical disability or while under anesthe ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk

    SBC: Altis Biosystems, Inc.            Topic: 300

    Project SummaryGI side effects, such as ulcers and diarrhea, represent the most common source of adverse events for pharmaceuticals. GI stem cells are responsible for repairing and replenishing GI epithelium, and pharmaceutical inhibition of these functions likely contribute to adverse event risk. Currently there are no high-throughput and cost-effective means of screening candidate therapeutics f ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Triage of Developmental and Reproductive Toxicants using an In vitro to In Vivo Extrapolation (IVIVE)-Toxicokinetic Computational modeling Application

    SBC: ScitoVation, LLC            Topic: R

    PROJECT SUMMARY A significant shift in the safety assessment of environmental chemicals is ongoing. This shift includes a reduction, or in some cases elimination, of traditional toxicity testing in animals with the implementation of new approach methodologies (NAMs). Although these emerging NAMs provide an attractive means for identifying teratogens and other developmental toxicants, the absence o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV

    SBC: MUCOMMUNE, LLC            Topic: NIAID

    Project Summary Respiratory syncytial virus (RSV) and metapneumovirus (MPV) are the two leading viral causes of death in infants and young children, and are major causes of respiratory illness in immunocompromised adults and the elderly. Unfortunately, there is currently no vaccine or effective therapy available for either infection. Synagis, a monthly intramuscular injection of the monoclonal ant ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Epigenomic analysis of cell-free nucleosomes for cancer research

    SBC: Epicypher, Inc.            Topic: 102

    PROJECT SUMMARYCell-free DNA (cfDNA) levels are elevated in the blood of individuals with cancer, leading to increased interest in liquid biopsy (LB)-based assays for disease diagnostics and monitoring. Despite this, current cfDNA assays are challenged by limited sensitivity and specificity to differentiate between cell types and disease states. cfDNA is primarily found as cell-free nucleosomes (c ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Intravaginal device for the treatment of pelvic pain and dyspareunia in female cancer survivors

    SBC: CERVU, INC            Topic: NICHD

    Summary: More than half of female cancer survivors will experience chronic pelvic pain and dyspareunia (painful intercourse) due to their cancer treatments. As the number of cancer survivors continues to grow, so too will the number of women in need of effective treatments for this life-altering condition. Pelvic floor physical therapists currently use several different devices during in-clinic an ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Ligand-Directed KRAS G12V Mutant-Specific Therapeutics

    SBC: ENFUEGO THERAPEUTICS, INC.            Topic: 102

    Project SummaryThe proto-oncogene KRAS is one of the most critical genes in cancer, yet, as a drug target, it has proven to be among the most elusive. A remarkable 30% of lung adenocarcinomas, 45% of colon, and 98% of pancreatic cancers are driven by KRAS mutations. These cancers account for the top 3 causes of cancer-related deaths in the United States. Most cancer associated KRAS mutations resul ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorderand Tolerance in the Treatment of Pain

    SBC: Amalgent Therapeutics, LLC            Topic: NIDA

    PROJECT SUMMARY Managing the complex risk-benefit profile of opioid therapeutics is a significant challenge for today’s physicians. Prescription opioid analgesics provide excellent pain relief but, at the same time, put patients in danger of severe adverse effects, most notably opioid use disorder (OUD). The current opioid crisis in the United States reflects these risks, as over 2.4 million Ame ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Polymer-antibody Conjugates as Long-acting Therapeutics for Ocular Diseases

    SBC: DELGEN BIOSCIENCES INC            Topic: 100

    PROJECT SUMMARY Wet age-related macular degeneration (AMD), a chronic eye disorder, is one of the leading causes of irreversible blindness and impacts approximately 3 million people (~200,000 each year) in the US alone. Wet AMD is characterized by aberrant angiogenesis under the retina and macular, which is induced by vascular endothelial growth factors (VEGFs). To this end, most therapeutic effor ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. High-throughput injectability screening of high concentration protein formulations by microfluidic quartz resonators

    SBC: QATCH TECHNOLOGIES LLC            Topic: 400

    The objective of this SBIR Direct Phase II proposal is to carry QATCH’s nanovisQ™ technology, which is a wide-shear-rate range and low volume viscometer for determining developability and injectability of biopharmaceutical formulations, from single-test sensors to high-throughput and automated format. This objective is motivated by the needs of the growing protein-based biopharmaceutical thera ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government